PMID- 28666098
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20220330
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 141
DP  - 2017 Oct
TI  - Anti-RhoJ antibody functionalized Au@I nanoparticles as CT-guided tumor 
      vessel-targeting radiosensitizers in patient-derived tumor xenograft model.
PG  - 1-12
LID - S0142-9612(17)30435-0 [pii]
LID - 10.1016/j.biomaterials.2017.06.036 [doi]
AB  - The clinical success of radiotherapy is greatly hampered due to its intolerable 
      off-target cytotoxicity induced by the high dose of radiation. Meanwhile, low 
      dose of irradiation greatly potentiates the intratumoral angiogenesis, which 
      promotes the local relapse and metastasis of tumor. Therefore, it is essential to 
      reduce the irradiation dosage while inhibiting the tumor angiogenesis during 
      radiotherapy. In this work, tumor vessel specific ultrafine Au@I nanoparticles 
      (AIRA NPs) are fabricated and used as targeted radiosensitizers. Due to the 
      presence of Au and iodine, these AIRA NPs exhibit superb X-ray attenuation for 
      contrast-enhanced computed tomography (CT). Once injected, these AIRA NPs bind 
      specifically to both newly formed tumor vessels in peri- and intratumoral regions 
      and pre-existing tumor vessels. Upon radiation under CT guidance, AIRA NPs 
      remarkably enhanced the killing efficacy against tumors in vivo with respect to 
      radiation alone or anti-angiogenesis chemotherapy. Meanwhile, down-regulation of 
      the level of circulating VEGF cytokine further indicates that our strategy can 
      eradicate tumor without risking the recurrence of hypoxia and angiogenesis. Our 
      demonstration provides a robust method of cancer therapy integrating good 
      biocompatibility, high specificity and relapse-free manner alternative to 
      traditional metal NPs enhanced radiotherapy.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Liu, Sen
AU  - Liu S
AD  - Institute of Materials Engineering, Collaborative Innovation Center of Chemistry 
      for Life Sciences, College of Engineering and Applied Sciences, Nanjing 
      University, Nanjing, Jiangsu, 210093, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Radiology, Drum Tower Hospital, School of Medicine, Nanjing 
      University, Nanjing, Jiangsu, 210093, China.
FAU - Xia, Luyao
AU  - Xia L
AD  - Institute of Materials Engineering, Collaborative Innovation Center of Chemistry 
      for Life Sciences, College of Engineering and Applied Sciences, Nanjing 
      University, Nanjing, Jiangsu, 210093, China.
FAU - Xu, Peipei
AU  - Xu P
AD  - Department of Hematology, Drum Tower Hospital, School of Medicine, Nanjing 
      University, Nanjing, Jiangsu, 210093, China.
FAU - Ding, Yin
AU  - Ding Y
AD  - State Key Laboratory of Analytical Chemistry for Life Science, School of 
      Chemistry and Chemical Engineering, Nanjing University, Nanjing, Jiangsu, 210023, 
      China. Electronic address: dingyin@nju.edu.cn.
FAU - Huo, Da
AU  - Huo D
AD  - Institute of Materials Engineering, Collaborative Innovation Center of Chemistry 
      for Life Sciences, College of Engineering and Applied Sciences, Nanjing 
      University, Nanjing, Jiangsu, 210093, China. Electronic address: 
      allicinhonda@163.com.
FAU - Hu, Yong
AU  - Hu Y
AD  - Institute of Materials Engineering, Collaborative Innovation Center of Chemistry 
      for Life Sciences, College of Engineering and Applied Sciences, Nanjing 
      University, Nanjing, Jiangsu, 210093, China. Electronic address: 
      hvyong@nju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170623
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Immunoconjugates)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 7440-57-5 (Gold)
RN  - EC 3.6.1.- (RHOJ protein, human)
RN  - EC 3.6.5.2 (rho GTP-Binding Proteins)
SB  - IM
MH  - Cell Line, Tumor
MH  - Female
MH  - Gold/chemistry/*therapeutic use
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Immunoconjugates/chemistry/*therapeutic use
MH  - Metal Nanoparticles/chemistry/*therapeutic use
MH  - Middle Aged
MH  - Neoplasms/*blood supply/diagnostic imaging/*therapy
MH  - Neovascularization, Pathologic/diagnostic imaging/drug therapy/pathology
MH  - Radiation-Sensitizing Agents/chemistry/*therapeutic use
MH  - Tomography, X-Ray Computed/methods
MH  - Xenograft Model Antitumor Assays
MH  - rho GTP-Binding Proteins/*analysis
OTO - NOTNLM
OT  - Angiogenesis
OT  - Anti-RhoJ antibody
OT  - Computed tomography
OT  - Nanoparticles
OT  - Radiosensitizer
EDAT- 2017/07/01 06:00
MHDA- 2018/05/01 06:00
CRDT- 2017/07/01 06:00
PHST- 2017/01/03 00:00 [received]
PHST- 2017/05/27 00:00 [revised]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
PHST- 2017/07/01 06:00 [entrez]
AID - S0142-9612(17)30435-0 [pii]
AID - 10.1016/j.biomaterials.2017.06.036 [doi]
PST - ppublish
SO  - Biomaterials. 2017 Oct;141:1-12. doi: 10.1016/j.biomaterials.2017.06.036. Epub 
      2017 Jun 23.